Advertisement
BGMS vs ORMP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BGMS is a Hold and ORMP is a Hold.
BGMS's RSI Oscillator leaves overbought zone
The 10-day RSI Indicator for BGMS moved out of overbought territory on September 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In 22 of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for BGMS crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BGMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BGMS broke above its upper Bollinger Band on September 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BGMS entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 68 cases where BGMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BGMS as a result. In 72 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for BGMS just turned positive on October 13, 2026. Looking at past instances where BGMS's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
BGMS moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +21.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where BGMS advanced for three days, in 179 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.836) is normal, around the industry mean (9.236). P/E Ratio (0.203) is within average values for comparable stocks, (38.255). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.212). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.410) is also within normal values, averaging (2.201).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. BGMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BGMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.
Momentum Indicator for ORMP turns negative, indicating new downward trend
ORMP saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 76 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ORMP entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ORMP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.622) is normal, around the industry mean (26.782). P/E Ratio (1.150) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). ORMP's Dividend Yield (0.053) is considerably higher than the industry average of (0.000). P/S Ratio (90.909) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BGMS | ORMP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 97 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 15 | |
PRICE GROWTH RATING 1..100 | 56 | 41 | |
P/E GROWTH RATING 1..100 | 1 | 91 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORMP's Valuation (1) in the Pharmaceuticals Other industry is in the same range as BGMS (30) in the Biotechnology industry. This means that ORMP’s stock grew similarly to BGMS’s over the last 12 months.
ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as BGMS (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to BGMS’s over the last 12 months.
ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for BGMS (100) in the Biotechnology industry. This means that ORMP’s stock grew significantly faster than BGMS’s over the last 12 months.
ORMP's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as BGMS (56) in the Biotechnology industry. This means that ORMP’s stock grew similarly to BGMS’s over the last 12 months.
BGMS's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ORMP (91) in the Pharmaceuticals Other industry. This means that BGMS’s stock grew significantly faster than ORMP’s over the last 12 months.
| BGMS | ORMP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 84% | N/A |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 81% |
| Advances ODDS (%) | 3 days ago 88% | 10 days ago 82% |
| Declines ODDS (%) | 7 days ago 90% | 2 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BGMS’s FA Score shows that 2 FA rating(s) are green while ORMP’s FA Score has 2 green FA rating(s).
- BGMS’s FA Score: 2 green, 3 red.
- ORMP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BGMS’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).
- BGMS’s TA Score: 5 bullish, 5 bearish.
- ORMP’s TA Score: 4 bullish, 5 bearish.
Price Growth
BGMS (@Building Products) experienced а +7.50% price change this week, while ORMP (@Biotechnology) price change was -4.79% for the same time period.
The average weekly price growth across all stocks in the @Building Products industry was +0.52%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was -6.41%.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.82%. For the same industry, the average monthly price growth was -18.40%, and the average quarterly price growth was -19.26%.
Reported Earning Dates
BGMS is expected to report earnings on Nov 18, 2026.
ORMP is expected to report earnings on Nov 16, 2026.
Industries' Descriptions
@Building Products (+0.52% weekly)The industry manufactures products used in the construction of residential and commercial buildings. The process involves using materials and other products, and processing them to create finished items such as doors, windows, light fittings, floor coverings, climate control products and other building components and home improvement products. Masco Corporation, Allegion PLC and Lennox International Inc. are major manufacturers of such products.
@Biotechnology (-7.82% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HOOY | 26.00 | 0.32 | +1.25% |
| YieldMax HOOD Option Income Strategy ETF | |||
| NMB | 23.21 | 0.27 | +1.18% |
| Simplify National Muni Bond ETF (NMB) | |||
| EWU | 46.82 | 0.12 | +0.26% |
| iShares MSCI United Kingdom ETF (EWU) | |||
| PMSE | 26.75 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF - September (PMSE) | |||
| BASG | 29.04 | -0.06 | -0.21% |
| Brown Advisory Sustainable Growth ETF (BASG) | |||